Female Pelvic Medicine and Reconstructive Surgery Webcast: Managing Obstruction after SUI Surgery
Female Pelvic Medicine and Reconstructive Surgery (FPMRS) comprises a significant component of the general urologist's practice. Over the past several years there has been an evolution in the diagnosis and treatment of female urologic conditions such as stress urinary incontinence, pelvic organ prolapse and overactive bladder. Technological and pharmacological advances are constantly occurring. Thus there is an educational need for increased knowledge, particularly related to advances in the specialty and understanding of current guidelines for the management of patients with female pelvic medicine conditions. FPMRS is now a boarded specialty (ABU and ABOG) and as such it is critical for the general urologist to keep pace with the ever evolving changes in the specialty if he/she is going to continue to treat women with FPMRS conditions.
This course is designed for:
- Practicing urologists
- Non-physician professionals
Upon completion of this course, participants should be able to:
- Identify women with relevant female pelvic medicine conditions that require counseling and or treatment
- Integrate physical examination, non-invasive testing and urodynamic tests into their practice to improve patient care of the female pelvic medicine patient through accurate diagnosis
- Describe available treatment options for female urologic conditions such as urinary incontinence, pelvic organ prolapse, recurrent UTI, bladder pain syndrome, overactive bladder, voiding dysfunction, vesicovaginal fistula, urethral diverticulum, urethral stricture disease and distinguish when a multi-disciplinary approach is appropriate
- Review the technical aspects of procedures for stress incontinence and female pelvic reconstruction that can be incorporated into surgical armamentarium including vaginal, open abdominal and robotic surgical options
- Discuss common complications of female pelvic reconstructive surgery and their management
- Understand the workup and management of the patients with neurogenic voiding dysfunction
Roger R. Dmochowski, MD: Allergan Consultant or Advisor
Deborah R. Erickson, MD: Nothing to Disclose
E. Ann Gormley, MD: SUFU Foundation Leadership Position No
Victor W. Nitti, MD: Astellas Health Publishing,Scientific Study or Trial; Allergan Health Publishing,Scientific Study or Trial; Serenity Pharmeuticals Investment Interest; Cook Myosite Scientific Study or Trial
Nirit Rosenblum, MD: Nothing to Disclose
Eric S. Rovner, MD: Astellas Consultant or Advisor,Meeting Participant or Lecturer; Allergan Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial; Medtronics Consultant or Advisor; NextMed Investment Interest; NIH/NIDDK Scientific Study or Trial; American medical systems Consultant or Advisor, Meeting Participant or Lecturer; Ferring Consultant or Advisor; Taris Consultant or Advisor,Scientific Study or Trial; Amphora Consultant or Advisor; ion innovations Scientific Study or Trial
J. Christian Winters, MD, FACS: Astellas, Inc Consultant or Advisor; Pfizer Consultant or Advisor; Allergan Consultant or Advisor; American Board of Urology Leadership Position; Society of Urodynamics, Female Pelvic Medicine and Urogential Reconstruction Leadership Position; Solace Scientific Study or Trial; StimGuard Consultant or Advisor
Education Council Disclosures:
Timothy Charles Brand, M.D.: Nothing to disclose
Peter Robert Carroll, MD MPH: NIH Scientific Study or Trial; Department of Defense Scientific Study or Trial; Myriad Genetics Scientific Study or Trial; AUA Update Leadership Position; Genomic Health Scientific Study or Trial
Sam S. Chang, MD: astellas Consultant or Advisor; NIH Scientific Study or Trial; Cold Genesys, Inc Scientific Study or Trial; GLG Consultant or Advisor; Bayer Consultant or Advisor
Pat Fox Fulgham, MD: Urology Clinics of North Texas Investment Interest
Matthew Thomas Gettman, M.D.: Nothing to disclose
Christina Giffin (OE Staff): Nothing to disclose
Inderbir Singh Gill ,M.D., M.Ch:. Hansen Medical Investment Interest; EDAP Consultant or Advisor; EDAP Consultant or Advisor; Mimic Consultant or Advisor
Misop Han, MD: Nothing to disclose
David Alan Hatch ,M.D.: Pfizer Scientific Study or Trial
Douglas A. Husmann MD: Nothing to disclose
Mark L. Jordan, M.D., F.A.C.S: Nothing to disclose
Louis Koncz ,PA-C: American Medical Systems Meeting Participant or Lecturer
Tracey Lynn Krupski, MD: Nothing to disclose
Cheryl Taylore Lee, MD: Endo Pharmaceuticals Scientific Study or Trial
Yair Lotan ,M.D.: abbott Scientific Study or Trial; Danone Consultant or Advisor, Scientific Study or Trial; Cepheid; Scientific Study or Trial; Pacific Edge Scientific Study or Trial; FKD Scientific Study or Trial; MDxHealth Consultant or Advisor; biocancell Scientific Study or Trial; Genomic Health Scientific Study or Trial; GenomeDx Biosciences Inc Scientific Study or Trial; photocure Scientific Study or Trial
Jill A. Macoska PhD: Nothing to disclose
Manoj Monga, MD, FACS: Fortec Other; endourology society Leadership Position
Victor William Nitti, MD (OE Staff): Astellas Health Publishing, Scientific Study or Trial; Allergan Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals Investment Interest; Cook Myosite Scientific Study or Trial
Gail S. Prins PhD: Nothing to disclose
Lee Richstone, M.D.: Nothing to disclose
Karl-Dietrich Sievert ,M.D., Ph.D.: AMS Meeting Participant or Lecturer; Karl Storz Meeting Participant or Lecturer; Medtronics Meeting Participant or Lecturer, Scientific Study or Trial; Allergen Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract Meeting Participant or Lecturer
Joseph A. Smith Jr.,M.D.: Nothing to disclose
Sean Patrick Stroup: Intuitive Surgical Meeting Participant or Lecturer; NeoTract Meeting Participant or Lecturer
Edouard John Trabulsi, M.D.: Nothing to disclose
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Non-physician Health Professionals: The AUA is not accredited to offer credit for non-physician health professionals. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
- 0.25 AMA PRA Category 1 Credit™
- 0.25 Non-Physician Participation